^
    BIOMARKER:

    KRAS G12R

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    KRAS G12R
    Colon Cancer
    cetuximab
    Resistant: B - Late Trials
    KRAS G12R
    CRC
    panitumumab
    Resistant: B - Late Trials
    KRAS G12R
    Pancreatic Adenocarcinoma
    selumetinib
    Sensitive: C3 – Early Trials
    KRAS G12R
    Pancreatic Cancer
    cobimetinib
    Sensitive: C3 – Early Trials
    KRAS G12R
    HCC
    sorafenib + BAY86-9766
    Sensitive: C3 – Early Trials
    KRAS G12R
    NSCLC
    erlotinib
    Resistant: C3 – Early Trials
    KRAS G12R
    Gastric Cancer
    imatinib
    Resistant: C4 – Case Studies
    KRAS G12R
    CRC
    sunitinib
    Resistant: D – Preclinical
    KRAS G12R
    Thyroid Gland Carcinoma
    trametinib + dasatinib
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Carcinoma
    trametinib
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Carcinoma
    dasatinib + SCH772984
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Carcinoma
    dasatinib + selumetinib
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Carcinoma
    dasatinib
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Anaplastic Carcinoma
    GSKJ4
    Sensitive: D – Preclinical